Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is expected to be announcing its earnings results after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $470.50 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $49.10 on Friday. The stock has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. The stock has a 50 day moving average price of $35.05 and a 200-day moving average price of $25.70. Hims & Hers Health has a one year low of $9.25 and a one year high of $72.98.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. The trade was a 56.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,343 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the transaction, the insider now directly owns 165,254 shares in the company, valued at $4,941,094.60. This represents a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,184,611 shares of company stock valued at $40,338,442. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $24.00 to $25.00 in a report on Friday, January 10th. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $42.00 to $60.00 in a report on Tuesday. Finally, BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.